Lactylation of histone variant MacroH2A1 at K134 regulates osteogenic differentiation of bone marrow mesenchymal stem cells
This study reveals that lactylation of the histone variant MacroH2A1 at lysine 134 epigenetically suppresses osteogenic differentiation of bone marrow mesenchymal stem cells by restricting chromatin accessibility, and that blocking this modification restores bone mass in osteoporotic mice, identifying it as a novel therapeutic target for osteoporosis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human skeleton is not a static frame of bone; it is a living tissue that constantly renews itself. This renewal relies on a delicate balance within the bone marrow, where stem cells decide whether to become bone-building cells or fat-storing cells. When this balance tips too far toward fat, bone density drops, leading to a condition known as osteoporosis, which makes bones fragile and prone to breaking. For decades, scientists have understood that the body's metabolism plays a role in this process. When cells break down sugar for energy, they produce a substance called lactate. While often viewed simply as a waste product that causes muscle soreness after exercise, recent discoveries have revealed that lactate acts as a powerful signal inside our cells, capable of turning genes on or off. This paper explores how this metabolic signal, specifically a chemical tag it places on the cell's genetic machinery, dictates whether stem cells build bone or store fat, offering a new perspective on why bones weaken with age.
Researchers at Jiujiang University and the Jiujiang Hospital of Traditional Chinese Medicine set out to understand exactly how lactate influences the fate of bone marrow stem cells. They began by observing these cells in a laboratory dish as they were guided to become bone cells. They found that as the cells started their journey toward becoming bone, the amount of lactate inside them naturally decreased. To test if this drop was important, they added extra lactate to the cells. The result was immediate: the extra lactate stopped the cells from turning into bone. Instead, the cells struggled to build the hard, mineralized structure that makes up bone. Conversely, when the researchers blocked the cells from producing lactate, the cells became much better at forming bone. This confirmed that high levels of lactate act as a brake on bone formation.
The team then asked a deeper question: how does a simple chemical like lactate send such a strong command to the cell's nucleus? They discovered that lactate attaches itself to specific proteins that package DNA, acting like a switch that controls which genes are active. Using advanced protein analysis, they identified a specific protein called MacroH2A1, which helps keep certain genes turned off. They found that when lactate levels are high, this protein gets tagged with a lactate molecule at a specific spot, known as position 134. This tag keeps the cell in a state where it cannot easily become bone. To prove this, the scientists created a version of the MacroH2A1 protein that could not be tagged by lactate. When they introduced this untaggable version into stem cells, the cells ignored the usual brakes and rapidly transformed into bone cells, producing high levels of the key proteins needed for bone growth.
To see if this finding held true in a living body, the researchers turned to a mouse model of osteoporosis. They created mice with low bone mass by removing their ovaries, a procedure that mimics the hormonal changes of menopause in humans. These mice typically lose bone and gain fat in their marrow. The team then injected a virus carrying the untaggable MacroH2A1 protein directly into the bone marrow of these mice. Over the course of twelve weeks, the treated mice showed a remarkable recovery. Their bones became denser, with more trabecular bone—the spongy, honeycomb-like structure inside bones that provides strength. Furthermore, the amount of fat in their bone marrow decreased significantly. The treatment effectively reversed the signs of bone loss, suggesting that removing the lactate tag from this specific protein can restore the body's ability to build bone.
The study also looked at the genetic landscape inside the cells to understand the mechanism. By mapping the accessibility of the DNA, they found that when the lactate tag was removed, the genetic material became more open in the regions that control bone development. This openness allowed the genes responsible for building bone to be read and expressed more easily. The research indicates that the lactate tag on MacroH2A1 acts as an epigenetic brake, locking stem cells in a state where they cannot differentiate into bone cells. By blocking this specific modification, the brake is released, allowing the cells to follow their natural path toward becoming bone.
This work provides a clear link between metabolism and the genetic regulation of bone health. It suggests that the accumulation of lactate, which can happen under conditions of stress or metabolic imbalance, may directly contribute to the weakening of bones by preventing stem cells from doing their job. While the researchers note that further studies are needed to identify the exact enzymes that add and remove these tags, their findings point to a promising new direction for treatment. If scientists can develop ways to prevent this specific lactate tag from forming, it might be possible to treat osteoporosis by helping the body's own stem cells rebuild bone more effectively, offering a potential solution for a condition that affects millions of people worldwide.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.